Navigation Links
OHSU Cancer Institute research gives hope for chemo holidays for men with advanced prostate cancer
Date:2/25/2008

PORTLAND, Ore. Oregon Health & Science University Cancer Institute researchers, in a first-of-its-kind study, have found that even men with advanced prostate cancer can take a much-needed safe break, or holiday, from chemotherapy.

The double-blind, randomized study, led by principal investigator Tomasz Beer, M.D., recently was published in the journal Cancer. Beer is the Grover C. Bagby Endowed Chair for Cancer Research, director of the OHSU Cancer Institute Prostate Cancer Program, and associate professor of medicine (hematology/medical oncology), OHSU School of Medicine.

Beer and his team wanted to know if men with metastatic, androgen-independent prostate cancer cancer that has spread from the prostate and is not affected by the male hormone, androgen could take a break from docetaxel, an intravenous chemotherapy delivery drug that is the gold standard treatment for androgen-independent prostate cancer. Docetaxel works by killing cancer cells and slowing cell growth. However, the drug also can cause side effects, such as hair loss, nausea, loss of appetite and increased chance for infections. Chemo holidays can be a much-needed vacation from these side effects.

Prior to this study, it wasnt known whether stopping chemotherapy would lead to treatment resistance.

We wanted to see if we could improve the quality of life for these patients by giving them time away from chemotherapy and possibly extend the time their cancer is controlled. Essentially, what we proved is that in selected subjects, chemotherapy holidays are feasible and provided meaningful breaks from treatment, said Beer.

This is the first multi-institutional trial to examine outcomes from intermittent chemotherapy. A total of 250 men participated. Of those, 18 percent entered the intermittent arm of the study. These men previously had responded well to chemotherapy.

The median duration of the first chemo holiday was 18 weeks. On resumption of chemoth
'/>"/>

Contact: Christine Decker
deckerch@ohsu.edu
503-494-8231
Oregon Health & Science University
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Conventional prognostic factors fail to explain better prostate cancer survival in most Asian men
2. Survival differences by race most apparent in advanced stages of breast cancer
3. MRI finds breast cancer before it becomes dangerous
4. Investigators uncover intriguing clues to why persistent acid reflux sometimes turns into cancer
5. Pathway links inflammation, angiogenesis and breast cancer
6. Radiologists encouraged to look beyond cancer for clinically unseen diseases
7. Diet high in meat, fat and refined grains linked to risk for colon cancer recurrence, death
8. Immune deficiency linked to a type of eye cancer
9. Drop in breast cancer incidence linked to hormone use, not mammograms
10. Breast cancer prevention practices vary across Canada
11. First biomarker discovered that predicts prostate cancer outcome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 2014 Richard Carlson, Managing Partner of ... with over 25 years experience. Mr. Carlson is ... areas related to EDI, B2B Commerce, RFID and Internet/Intranet ... Advisory Board member for Pharmaceutical Commerce Magazine and a ... Group is a management and technology consulting firm focused ...
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. 21, 2014 (HealthDay ... be showing a genetic propensity for obesity as toddlers, a ... linked to increased body fat, but the same genes in ... researchers said. At 1 year, kids with these genes ... however, these genes were linked to excessive weight gain, the ...
(Date:10/22/2014)... (HealthDay News) -- Two sisters in high school have ... Ilina and Medha Krishen use electronic stethoscopes, which electronically ... in breathing patterns or heartbeats. Ilina, a senior ... to find a way to detect early lung damage ... electronic stethoscope, Ilina recorded one breath cycle each from ...
(Date:10/22/2014)... HealthDay Reporter TUESDAY, Oct. 21, ... vitro fertilization (IVF) -- the incubation of embryos in a ... inside the vagina, new research suggests. Scientists from the ... INVOcell, might sharply cut costs for pricey IVF procedures among ... to those who don,t live near big-city assisted reproduction centers, ...
(Date:10/22/2014)... HealthDay Reporter , MONDAY, Oct. 20, ... tightened guidelines for health workers treating Ebola patients, now requiring ... a respirator at all times. The U.S. Centers for ... after two Dallas nurses contracted Ebola while caring for the ... Thomas Eric Duncan. Nina Pham is currently being treated for ...
Breaking Medicine News(10 mins):Health News:Rich Carlson and Marc Duey to Hold Workshop at CBI’s Specialty Pharmacy and Distribution Networks Conference 2Health News:Tall, Heavy 1-Year-Olds May Be at Risk for Obesity Later, Study Finds 2Health News:Teen Sisters Develop Ways to Measure Lung, Heart Damage 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 4Health News:CDC Tightens Rules on Caring for Ebola Patients 2Health News:CDC Tightens Rules on Caring for Ebola Patients 3
... testing of 12 lymph nodes may not be as useful ... -- A new study is questioning the conventional wisdom of ... cancer surgery. , These post-op checks have been thought to ... is casting that notion in doubt. , "What we are ...
... of thousands of lives saved each year through immunization, ... The incidence of vaccine-preventable deaths has reached an all-time ... shows. , The study, by researchers at the U.S. ... childhood vaccinations have reduced the death rates from seven ...
... white paper is now,available to help hospitals prepare ... unannounced surveys at:, http://www.eheinc.com/jcaho.htm . Titled "Continuous ... Policy within the Environment of Care, and authored ... consulting firm,the white paper reviews the common barriers ...
... advancement in aspirin delivery ... ... out Fasprin(R), a patented, 81 milligram aspirin tablet that,dissolves rapidly in ... for the millions of Americans who maintain a,daily aspirin routine and ...
... than Generic Store-Brand Infant,Formulas, Says Mayo Clinic Internet Resource; Mothers ... ... Nov. 13 The Mayo Clinic, a not-for-,profit medical practice ... complex illness, now offers an online resource for,parents who choose ...
... Walk on November 17th will Raise Awareness and Funds ... the Homeless Capital of America, LOS ANGELES, Nov. ... that 3000 marchers have signed up to fight homelessness ... first-ever 5k,family walk called HomeWalk in Exposition Park near ...
Cached Medicine News:Health News:Study Challenges Colon Cancer Surgery Follow-Up 2Health News:Study Challenges Colon Cancer Surgery Follow-Up 3Health News:Vaccine-Preventable Deaths Reach New Low in U.S. 2Health News:Vaccine-Preventable Deaths Reach New Low in U.S. 3Health News:Free White Paper Details Hospital Strategies for Meeting Joint Commission Compliance Requirements in the Environment of Care 2Health News:New, No-Swallow Fasprin(R) Reduces Problems Associated with Daily Aspirin Regimen 2Health News:Mayo Clinic Supports Store-Brand Infant Formulas 2Health News:United Way of Greater Los Angeles and Fannie Mae Foundation Announce 3000 Marchers for HomeWalk 2007 2Health News:United Way of Greater Los Angeles and Fannie Mae Foundation Announce 3000 Marchers for HomeWalk 2007 3
(Date:10/22/2014)... 2014  CryoLife, Inc. (NYSE: CRY ), ... on cardiac and vascular surgery, announced today that ... Officer, has been elected to the Company,s Board of ... G. Anderson , Executive Chairman of CryoLife, stated, "Since joining ... an excellent leader who is well positioned to maximize ...
(Date:10/22/2014)... 21, 2014   BioNano Genomics , the ... research centers to purchase an Irys™ System . ... Cancer Institute (NCI), NIH Intramural Sequencing Center (NISC) and ... obtaining a comprehensive view of a genome was ... does not deliver the scalability or reliability to ...
(Date:10/22/2014)... 2014 Influenza will affect as many as 200,000 ... the United States as high as 49,000 people.  ... is from person to person in respiratory droplets of coughs ... of death, but kills much fewer people each year than ... human fluids including sweat, saliva, blood and other bodily fluids. ...
Breaking Medicine Technology:Pat Mackin Joins CryoLife Board of Directors 2Pat Mackin Joins CryoLife Board of Directors 3BioNano's Irys System Adopted by Leading Genomics Centers for Comprehensive Detection of Human Genome Structural Variation 2BioNano's Irys System Adopted by Leading Genomics Centers for Comprehensive Detection of Human Genome Structural Variation 3WholeHealth Products is proud to be releasing its Influenza A and B combo test, on the heels of the announcing of its phase 2 completion of the Rapid Ebola Test 2
... PARIS and TARRYTOWN, N.Y., March 10, 2011 ... ) and Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN ... trial evaluating the investigational agent aflibercept (VEGF Trap) for ...  The data showed that adding aflibercept to the chemotherapy ...
... BioSpecifics Technologies Corp. (Nasdaq: BSTC ), ... today announced that BioSpecifics, President, Tom Wegman, will present ... Stock Conference on Monday, March 14, 2011, at 11:30 ... Niguel, California. A live webcast of the ...
Cached Medicine Technology:Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer 2Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer 3Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer 4Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer 5Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer 6Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer 7
This set is designed to introduce the low vision practitioner to the Keeler telescopic system....
... Featuring up to 20 ... examination in the vertical, ... plus the option to ... corneal transillumination., ,Filters include ...
Comes complete in its own carrying case. There are 24 lenses, 13mm diameter -6D to +6D in 0.5D steps. Mounted in tough, yet light alloy frame....
... Interventions, like all important missions, ... guide you to your destination. ... you this dependability. So you ... the intervention and not have ...
Medicine Products: